Alan Lewis, PhD

Alan J. Lewis, PhD currently serves as CEO and Director of Diavecs, a private biotech company and is a director of Batu Biologics, Capella Therapeutics, Targazyme, HabitDX, Arkay and Biomarin. He has served as President and CEO of Medistem, Ambit Biosciences, the Juvenile Diabetes Foundation, Novocell and Signal Pharmaceuticals. He was President of the Signal Research Division of Celgene after their acquisition of Signal. Dr. Lewis held a number of positions at Wyeth including VP of Research. He has published over 120 manuscripts and has written and edited seven books. Dr. Lewis was a Research Associate at Yale University. He received a BS in Physiology and Biochemistry from Southampton University and a PhD in pharmacology from the University of Wales in Cardiff. He is an honorary fellow of the University of Wales in Swansea.